MapLight Therapeutics Announces Initiation of Phase 2 Trial of Novel M1/M4 Muscarinic Agonist ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

MapLight Therapeutics today announced the initiation of a Phase 2 study to evaluate the efficacy, safety and tolerability of ML-007C-MA, an investigational novel M1/M4 agonist, as a potential ...
JSTOR Daily

Temporal regulation of nicotinic acetylcholine receptor subunits supports central cholinergic synapse development in Drosophila

Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, No. 23 (June 8, 2021), pp. 1-12 (12 pages) The construction and maturation of the postsynaptic apparatus are ...
Healio

Exposure to cholinergic compounds, personal care products may lead to early puberty

Please provide your email address to receive an email when new articles are posted on . Musk ambrette, found in some personal care products, increased stimulating activity in kisspeptin receptor cells ...
Healio

FDA approves first new class of schizophrenia treatment in more than 30 years

Please provide your email address to receive an email when new articles are posted on . Cobenfy is the first antipsychotic medication to treat schizophrenia by targeting cholinergic receptors. The ...
Psychology Today

Will New Antipsychotics for Schizophrenia Be Game Changers?

In a previous article, I made the case that little has changed within the antipsychotic drug landscape over the past 70 years since the only effective medications for the treatment of schizophrenia ...
Pharmabiz

MapLight Therapeutics initiates phase 2 trial of novel M1/M4 muscarinic agonist ML-007C-MA to treat Alzheimer’s disease psychosis

MapLight Therapeutics initiates phase 2 trial of novel M1/M4 muscarinic agonist ML-007C-MA to treat Alzheimer’s disease psychosis: San Francisco Thursday, September 18, 2025, 17 ...